MX2019009443A - Metodos para tratar la influenza. - Google Patents

Metodos para tratar la influenza.

Info

Publication number
MX2019009443A
MX2019009443A MX2019009443A MX2019009443A MX2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A MX 2019009443 A MX2019009443 A MX 2019009443A
Authority
MX
Mexico
Prior art keywords
methods
treating influenza
prevention
treatment
relates
Prior art date
Application number
MX2019009443A
Other languages
English (en)
Inventor
Ewart Gary
Luscombe Carolyn
Original Assignee
Biotron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by Biotron Ltd filed Critical Biotron Ltd
Publication of MX2019009443A publication Critical patent/MX2019009443A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al tratamiento o prevención de infección por el virus de la influenza. En particular, la presente invención se refiere al uso de N-carbamimidoil-5-(1-metil - 1H-pirazol-4-il)-2-naftamida, o una sal farmacéuticamente aceptable de la misma, en el tratamiento o prevención de infección por el virus de la influenza.
MX2019009443A 2017-02-08 2018-02-07 Metodos para tratar la influenza. MX2019009443A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (1)

Publication Number Publication Date
MX2019009443A true MX2019009443A (es) 2019-12-16

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009443A MX2019009443A (es) 2017-02-08 2018-02-07 Metodos para tratar la influenza.

Country Status (13)

Country Link
US (1) US10918623B2 (es)
EP (1) EP3579833B1 (es)
JP (1) JP7019727B2 (es)
KR (1) KR102607599B1 (es)
CN (1) CN110325187B (es)
AU (1) AU2018218179B2 (es)
BR (1) BR112019016316A2 (es)
CA (1) CA3052503A1 (es)
ES (1) ES2910136T3 (es)
MX (1) MX2019009443A (es)
RU (1) RU2769317C2 (es)
SG (1) SG11201907034PA (es)
WO (1) WO2018145148A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
MA42819A (fr) 2015-09-16 2018-07-25 Gilead Sciences Inc Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
TW201836615A (zh) 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
US11773122B2 (en) 2020-08-24 2023-10-03 Gilead Sciences. Inc. Phospholipid compounds and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
US20230000873A1 (en) 2021-05-26 2023-01-05 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CA3238183A1 (en) * 2021-11-24 2023-06-01 Michelle Miller Methods of treating sars-cov-2 infection
TW202345786A (zh) 2022-03-02 2023-12-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023168194A1 (en) 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20230382940A1 (en) 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2023239665A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
WO2024006461A1 (en) 2022-06-30 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902017B1 (en) 2005-06-24 2014-03-26 Biotron Limited Antiviral acylguanidine compounds
ES2614269T3 (es) * 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
EP4342545A2 (en) * 2014-07-07 2024-03-27 Elian LLC Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CN110870864B (zh) 2018-08-29 2021-09-24 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
CA3052503A1 (en) 2018-08-16
US10918623B2 (en) 2021-02-16
RU2019126746A (ru) 2021-03-09
EP3579833B1 (en) 2022-01-05
CN110325187B (zh) 2022-09-30
BR112019016316A2 (pt) 2020-03-31
JP2020506243A (ja) 2020-02-27
EP3579833A4 (en) 2021-01-13
AU2018218179B2 (en) 2023-05-04
KR102607599B1 (ko) 2023-11-28
KR20190112051A (ko) 2019-10-02
AU2018218179A1 (en) 2019-08-22
US20200093796A1 (en) 2020-03-26
SG11201907034PA (en) 2019-08-27
ES2910136T3 (es) 2022-05-11
RU2019126746A3 (es) 2021-05-28
WO2018145148A1 (en) 2018-08-16
CN110325187A (zh) 2019-10-11
JP7019727B2 (ja) 2022-02-15
RU2769317C2 (ru) 2022-03-30
EP3579833A1 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
MX2019009443A (es) Metodos para tratar la influenza.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12017502103A1 (en) Methods and kits for treating depression
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2017001461A (es) Terapia de combinacion.
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018001684A (es) Metodo de curacion de heridas.
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EA201990712A1 (ru) Лечение рассеянного склероза посредством chs-131